Studies suggest that ZNF185 is downregulated in multiple epithelial cancers (e.g., prostate, lung, and pancreatic cancers) [19], likely due to its transcriptional activation by wild-type p53 upon DNA damage [20]. This evidence concerns the gene TP53 and pancreatic neoplasm.